Navigation Links
Reata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
Date:6/16/2011

vision in San Antonio, Texas, who screened the first patient of the study. "There are few therapeutic options available today that slow the progression of CKD. Results from the Phase 2 BEAM trial suggest that bardoxolone methyl may improve measures of kidney function in patients with moderate to severe CKD and Type 2 diabetes.  We look forward to further evaluating the drug candidate's effects on clinical outcomes in this patient population."

Final results from the 52-week Phase 2b BEAM study will be presented during a Late-Breaking Clinical Trials session on June 24 at the 2011 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Prague, Czech Republic.

About Chronic Kidney Disease

Chronic kidney disease (CKD) is a progressive loss of kidney function over a period of months or years that can be caused by a number of conditions, including diabetes and high blood pressure. CKD is a highly prevalent condition worldwide with numbers expected to rise over the next decade. In the United States there are more than 26 million patients with CKD, and more than 500,000 patients with ESRD.

About Bardoxolone Methyl

Bardoxolone methyl is a novel, first-in-class antioxidant inflammation modulator (AIM).  Bardoxolone methyl is an Nrf2 activator, thereby inducing the transcription of genes that reduce oxidative stress and suppress important inflammatory mediators.

In January 2010, Reata and Kyowa Hakko Kirin (KHK) announced a licensing agreement providing KHK with the exclusive rights to develop and commercialize bardoxolone methyl in Japan and other selected Asian markets. In September 2010, Reata formed a strategic partnership with Abbott for the commercialization of bardoxolone methyl in other ex-U.S. markets. Reata retains exclusive rights to bardoxolone methyl in the U.S.

About Reata Pharmaceuticals

Reata Pharmaceuticals is the leader in disco
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
2. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
3. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
4. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
7. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
8. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
9. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
10. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
11. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)...  Over 100 million adults suffer from chronic pain ... daily. Chronic and acute pain dramatically impacts quality of ... fulfill the need for non-surgical, interventional solutions and medication ... On October 28th, a new pain management center opened ... community.  This new facility boasts cutting edge technologies ...
(Date:11/26/2014)... ® , Inc. (NASDAQ: BIOS ) announced today that ... present at the Bank of America Merrill Lynch 2014 Leveraged Finance ... , , Wednesday, December 3, 2014 , , , , ... , Location: , , , Boca Raton Resort and Club, Florida ... BioScrip, Inc. is a leading national provider of infusion ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3New Pain Management Center Opens in Cumberland, Md. 2
... Germany, June 11, 2007 /PRNewswire/ -- NovaCardia, Inc.,today ... trial of,KW-3902, an adenosine A1 receptor antagonist in ... heart failure (CHF),that indicate a strong trend toward ... KW-3902 experienced a higher rate of,improvement in dyspnea, ...
... Results Presented at the 12th Congress of ... 11, 2007 /PRNewswire-FirstCall/ --,Immunomedics, Inc. , a ... treat cancer and other serious,diseases, today announced ... EHA in Vienna, Austria, showed positive responses ...
Cached Medicine Technology:Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 2Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5
(Date:11/27/2014)... (PRWEB) November 27, 2014 Tylenol lawsuits ... were allegedly injured by the medication are continuing to ... litigation is looking ahead to a status conference in ... a Scheduling Order issued earlier this year, a conference ... 16th at 10:00 a.m. Items likely to be discussed ...
(Date:11/27/2014)... November 27, 2014 “LAB.C” was featured on ... the latest and coolest technology products available to consumers. Mallory ... product review and shared with viewers the company ... and Android devices. , Consumers love portability and functionality. ... Cable Case for the iPhone5 and 5S has a portable ...
(Date:11/27/2014)... HealthPostures, a leading national ... has announced that it has entered into a ... partnership will put HealthPostures' products into central Indiana’s ... addition to having its products sold through Commercial ... products with the business decision makers in the ...
(Date:11/27/2014)... Marietta, GA (PRWEB) November 27, 2014 "The ... the whole month of December is full of laughter as ... Tandy Wilson won by making a sweater from scratch. " ... lit Christmas tree, and if that weren't ridiculous enough, the ... on top. , For those interested in participating this ...
(Date:11/27/2014)... Delhi, India (PRWEB) November 27, 2014 Ethane ... has announced it will provide a 10% Christmas discount on ... month of December. The discount offer will begin on 1 ... 2014. , About this offer, a PPC professional working ... for all, especially for small businesses, as this big discount ...
Breaking Medicine News(10 mins):Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... problem drinkers using alcohol to cope with personal problems ... drinking into adulthood, a recent study suggests. , The ... are still high-risk drinkers by age 34 may have ... development that typically occurs during college, including the ability ...
... 24 Conseco, Inc. (NYSE: CNO ) ... existing $911.8 million senior secured credit agreement. Banc ... in connection with the amendment. The amendment, which ... in the current repayment schedule, is expected to provide ...
... "Hangin, Out With My Baby," ... with their newborns, infants and toddlers, will be distributed free ... hospitals throughout the U.S. Starting today with a live concert ... CDs will be given away this year by participating hospitals.Arranged ...
... Cancer Society Cancer Action Network, the American Heart Association, ... Kids applaud Senator Frank Lautenberg of New Jersey,s call ... authority and immediately remove e-cigarettes from the market. ... publications during the past few weeks saying that e-cigarettes ...
... help metropolitan public health agencies,prepare to deliver essential ... or natural disease outbreak has succeeded in improving,the ... Corporation study. , Researchers found that the federal ... areas, appears to have improved,agencies, ability to rapidly ...
... experts at The University of Nottingham have shown that ... the quality of life for many community-based dialysis patients. ... journal Biomaterials , have shown that the catheter ... wider variety of pathogens and protect Continuous Ambulatory Peritoneal ...
Cached Medicine News:Health News:Study helps identify college drinkers who might continue excessive drinking as adults 2Health News:Study helps identify college drinkers who might continue excessive drinking as adults 3Health News:Study helps identify college drinkers who might continue excessive drinking as adults 4Health News:Study helps identify college drinkers who might continue excessive drinking as adults 5Health News:Conseco Seeks Amendment of Its Credit Facility 2Health News:Conseco Seeks Amendment of Its Credit Facility 3Health News:Conseco Seeks Amendment of Its Credit Facility 4Health News:Project 'Hangin' Out With My Baby' Launches National Children's Music Giveaway Campaign at California Hospital Medical Center in Los Angeles 2Health News:Project 'Hangin' Out With My Baby' Launches National Children's Music Giveaway Campaign at California Hospital Medical Center in Los Angeles 3Health News:Statement of the American Cancer Society Cancer Action Network, American Heart Association, American Lung Association and the Campaign for Tobacco-Free Kids 2Health News:Study finds program has improved health agencies' preparedness for bioterror and disease outbreaks 2Health News:Anti-microbial catheter to cut infection risk for dialysis patients 2Health News:Anti-microbial catheter to cut infection risk for dialysis patients 3
... molecular biology grade, standard melting temperature agarose that ... DNA, RNA, and PCR products = 1 kb. ... processing and blotting. Performance testing of NuSieve 3:1 ... to 1,000 bp, though this agarose is capable ...
... is a standard gelling temperature, high gel ... than 1,000 bp. This Genetic Technology Grade™ ... DNA electrophoresis. DNA recovered from SeaKem GTG ... ligated. SeaKem GTG Agarose is extensively performance ...
... gel strength, high electrophoretic mobility, and ... is the superior choice for CHEF ... easy to handle at concentrations as ... run times. Low background staining also ...
... general-purpose agarose, like the entire line of ... grade. This ensures that DNA recovered from ... compromising quality. Certified molecular biology agarose is ... molecular weight, resulting in a gel structure ...
Medicine Products: